Acquisition of Molecular Insight Pharmaceuticals, Inc (Details) (USD $)	1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 18, 2013	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Original Shares Issued For Acquisition	4,566,210
Shares For Acquisition Held In Escrow	500,000
Shares For Acquisition Returned From Escrow	93,847
Maximum Milestone Payment Specified Commercial Events		$ 23,000,000			$ 23,000,000
Maximum Milestone Payment For Achieving Sales Targets		70,000,000			70,000,000
Closing price of Progenics' common shares	$ 2.83
Business Acquisition, Cost of Acquired Entity, Transaction Costs					790,000
Business Acquisition Contributed Revenue					884,000
Business Acquisition Contributed Net Loss					11,379,000
Equity issuance costs in connection with acquisition of subsidiary			45,000		45,000	0	0
Progenics common stock consideration	11,265,000
Acquisition-related contingent consideration liability	15,900,000	15,700,000		0	15,700,000	0	0
Business Entity Acquisition, Cost of Acquired Entity, Purchase Price	27,165,000	11,265,000		0	11,265,000	0	0
Cash acquired in acquisition of subsidiary	1,888,000
Business Acquisition, Purchase Price Allocation, Current Assets, Receivables	56,000
Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets	529,000
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment	249,000
Business Acquisition, Purchase Price Allocation, Current Liabilities	(2,876,000)
Deferred tax liability - long term	(12,683,000)	(12,321,000)		0	(12,321,000)	0
Business Entity Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net	(12,837,000)
Intangible assets	32,300,000
Business Acquisition Tangible And Intangible Assets Acquired Liabilities Assumed	19,463,000
Goodwill	7,702,000
Business Acquisition Transaction Costs Excluded From Pro Forma Information					790,000
Business Acquisition, Pro Forma Revenue		2,968,000		12,801,000	7,867,000	18,235,000
Business Acquisition, Pro Forma Net Income (Loss)		(8,551,000)		(3,458,000)	(43,736,000)	(57,877,000)
Business Acquisition Pro Forma Earnings Per Share Basic And Diluted		$ (0.14)		$ (0.08)	$ (0.78)	$ (1.48)
Azedra [Member]
Fair Value Measurements [Abstract]
Discount rate	15.00%
Beginning of significant cash inflows - year	2017
Fair Value	4,900,000
MIP 1404 [Member]
Fair Value Measurements [Abstract]
Discount rate	18.00%
Beginning of significant cash inflows - year	2017
Fair Value	23,200,000
Onalta [Member]
Fair Value Measurements [Abstract]
Discount rate	15.00%
Beginning of significant cash inflows - year	2014
Fair Value	1,500,000
Small Molecule [Member]
Fair Value Measurements [Abstract]
Discount rate	20.00%
Beginning of significant cash inflows - year	2021
Fair Value	2,700,000
Contingent Consideration Liability [Member]
Fair Value Measurements [Abstract]
Fair Value	$ 15,900,000
Minimum [Member] | Contingent Consideration Liability [Member]
Fair Value Measurements [Abstract]
Discount rate	10.00%
Beginning of significant cash inflows - year	2016
Maximum [Member] | Contingent Consideration Liability [Member]
Fair Value Measurements [Abstract]
Discount rate	12.50%
Beginning of significant cash inflows - year	2022